scholarly journals Adverse Effects of Plant Food Supplements and Plants Consumed as Food: Results from the Poisons Centres-Based PlantLIBRA Study

2016 ◽  
Vol 30 (6) ◽  
pp. 988-996 ◽  
Author(s):  
Saskia Lüde ◽  
Sarah Vecchio ◽  
Sandra Sinno-Tellier ◽  
Aymeric Dopter ◽  
Harriet Mustonen ◽  
...  
Keyword(s):  
Adverse Effects ◽  
Food Supplements ◽  
Plant Food ◽  
Poisons Centres

Adverse effects of Plant Food Supplements and botanical preparation: Data collected during the EU project PlantLIBRA

2016 ◽  
Vol 258 ◽  
pp. S23-S24 ◽  
Author(s):  
Patrizia Restani ◽  
Alessandro Ceschi ◽  
Gianfranco Frigerio ◽  
Francesca Colombo ◽  
Saskia Lüde ◽  
...  
Keyword(s):  
Adverse Effects ◽  
Food Supplements ◽  
Plant Food ◽  
Eu Project ◽  
The Eu

scholarly journals Adverse Effects of Plant Food Supplements Self-Reported by Consumers in the PlantLIBRA Survey Involving Six European Countries

PLoS ONE ◽  
2016 ◽  
Vol 11 (2) ◽  
pp. e0150089 ◽  
Author(s):  
Patrizia Restani ◽  
Chiara Di Lorenzo ◽  
Alicia Garcia-Alvarez ◽  
Mihaela Badea ◽  
Alessandro Ceschi ◽  
...  
Keyword(s):  
Adverse Effects ◽  
Food Supplements ◽  
European Countries ◽  
Plant Food

scholarly journals Adverse effects of plant food supplements and botanical preparations: a systematic review with critical evaluation of causality

2015 ◽  
Vol 79 (4) ◽  
pp. 578-592 ◽  
Author(s):  
Chiara Di Lorenzo ◽  
Alessandro Ceschi ◽  
Hugo Kupferschmidt ◽  
Saskia Lüde ◽  
Elizabeth De Souza Nascimento ◽  
...  
Keyword(s):  
Systematic Review ◽  
Adverse Effects ◽  
Critical Evaluation ◽  
Food Supplements ◽  
Plant Food

A Review of Recent Patents (2016-2019) on Plant Food Supplements with Potential Application in the Treatment of Neurodegenerative and Metabolic Disorders

2020 ◽  
Vol 11 (2) ◽  
pp. 145-153 ◽  
Author(s):  
Rosalba Leuci ◽  
Leonardo Brunetti ◽  
Antonio Laghezza ◽  
Paolo Tortorella ◽  
Fulvio Loiodice ◽  
...  
Keyword(s):  
Metabolic Disorders ◽  
Food Supplements ◽  
Plant Food ◽  
Fortified Foods ◽  
Patent Review ◽  
Novel Strategy ◽  
Lifestyle Related Diseases ◽  
Near Future ◽  
Prevention And Therapy

In the near future, it is expected that the prevalence of illnesses related to the increasing life expectancies and quality of life, such as neurodegenerative diseases and cardiovascular diseases related to metabolic disorders, will soar to unprecedented levels, leading to high socioeconomic costs. To address this rising threat, natural products are emerging as a novel strategy for the prevention and therapy of these ages- and lifestyle-related diseases, thanks to their high marketability and few side effects. In this patent review, we summarize selected patents for food supplements, functional and fortified foods, filed from 2016 to 2019, categorizing them based on the biological activity of their components.

scholarly journals Risk Assessment of "Other Substances" – L-threonine

2020 ◽  
pp. 63-65
Author(s):  
Martinus Løvik ◽  
Livar Frøyland ◽  
Margaretha Haugen ◽  
Sigrun Henjum ◽  
Kristin Holvik ◽  
...  
Keyword(s):  
Risk Assessment ◽  
Food Safety ◽  
Adverse Effects ◽  
Health Effects ◽  
Food Supplements ◽  
Risk Assessments ◽  
Adverse Health Effects ◽  
Adverse Health ◽  
Other Substances ◽  
One Year

The Norwegian Scientific Committee for Food Safety (Vitenskapskomiteen for mattrygghet, VKM) has, at the request of the Norwegian Food Safety Authority (Mattilsynet; NFSA), assessed the risk of "other substances" in food supplements and energy drinks sold in Norway. VKM has assessed the risk of doses given by NFSA. These risk assessments will provide NFSA with the scientific basis while regulating "other substances" in food supplements. "Other substances" are described in the food supplement directive 2002/46/EC as substances other than vitamins or minerals that have a nutritional and/ or physiological e ffect. It is added mainly to food supplements, but also to energy drinks and other foods. In this series of risk assessments of "other substances" the VKM has not evaluated any claimed beneficial effects from these substances, only possible adverse effects. The present report is a risk assessment of specified doses of L-threonine in food supplements, and it is based on previous risk assessments and articles retrieved from literature searches. According to information from NFSA, L-threonine is an ingredient in food supplements sold in Norway. NSFA has requested a risk assessment of 1000, 1200, 1500, 2000 and 2400 mg/day of L-threonine from food supplements.  L-threonine is an essential amino acid not known to cause any adverse health effects. Previous reports do not indicate a tolerable upper intake level, apart from an approval of a dose of 1150 mg/day by the Scientific Committee of the Spanish Agency for Food Safety and Nutrition (AESAN). Long-term studies in humans were not found. The only available human studies were: a small uncontrolled one-year pilot study with doses ranging from 0.5 to 2.5 g/day, one eight-week randomised controlled trial (RCT) using a dose of 7.5 g/day, and two 2-week RCTs using doses of 6 and 4.5 g/day. No adverse effects (diary method of registration of adverse effects) were reported in the eight-week clinical trial, and the only adverse effects observed in the two-week trials were one case of indigestion and one case of diarrhoea. A four-week rodent toxicity study indicated a no observed adverse effect level (NOAEL) of 854.3 mg/kg bw per day (only dose tested, no adverse effects observed).  The value used for comparison with the estimated exposure in the risk characterisation is the NOAEL defined in an 8-week randomised placebo controlled study in humans, 7500 mg/day. For a 70-kg individual, this corresponds to 107 mg/kg bw per day. Two human two-week studies and a small one-year pilot study support the notion that this dose will be well tolerated. The overall mean threonine intake according to NHANES III (3 g/day) is slightly larger than the doses requested for evaluation in the present risk assessment. No studies in children (10 to <14 years) and adolescents (14 to <18 years) were identified. Based on the included literature there was no evidence indicating that age affects the tolerance for relevant doses of threonine. Therefore, in this risk characterisation a tolerance as for adults, based on body weight, was assumed for these age groups. VKM concludes that: In adults (≥18 years), the specified doses 1000, 1200, 1500, 2000 and 2400 mg/day L-threonine in food supplements are unlikely to cause adverse health effects. In adolescents (14 to <18 years), the specified doses 1000, 1200, 1500, 2000 and 2400 mg/day L-threonine in food supplements are unlikely to cause adverse health effects. In children (10 to <14 years), the specified doses 1000, 1200, 1500, 2000 and 2400 mg/day L-threonine in food supplements are unlikely to cause adverse health effects. Children younger than 10 years were not within the scope of the present risk assessment.

scholarly journals Plant Food Supplements with Anti-Inflammatory Properties: A Systematic Review (II)

2013 ◽  
Vol 53 (5) ◽  
pp. 507-516 ◽  
Author(s):  
Chiara Di Lorenzo ◽  
Mario Dell’agli ◽  
Mihaela Badea ◽  
Lorena Dima ◽  
Elisa Colombo ◽  
...  
Keyword(s):  
Systematic Review ◽  
Food Supplements ◽  
Plant Food ◽  
Anti Inflammatory

Regulations applicable to plant food supplements and related products in the European Union

2011 ◽  
Vol 2 (12) ◽  
pp. 710 ◽  
Author(s):  
Vittorio Silano ◽  
Patrick Coppens ◽  
Ainhoa Larrañaga-Guetaria ◽  
Paola Minghetti ◽  
René Roth-Ehrang
Keyword(s):  
European Union ◽  
Food Supplements ◽  
Plant Food ◽  
The European Union

scholarly journals Analysis of pharmaceutical adulterants in plant food supplements by UHPLC-MS/MS

2017 ◽  
Vol 99 ◽  
pp. 219-227 ◽  
Author(s):  
Paula Paíga ◽  
Manuela J.E. Rodrigues ◽  
Manuela Correia ◽  
Joana S. Amaral ◽  
M. Beatriz P.P. Oliveira ◽  
...  
Keyword(s):  
Food Supplements ◽  
Plant Food
Sign in / Sign up

Export Citation Format

Share Document